
Title: A discrete choice experiment involving 1,230 young people across England to identify factors that influence young people’s preferences for emerging technologies for Chlamydia testing and treatment.

Authors:
Sue Eaton, MSc, Warwick Medical School, University of Warwick, Coventry, UK
Dr Deborah Biggerstaff, PhD, Warwick Medical School, University of Warwick, Coventry, UK.
Dr Joshua Pink, PhD, National Institute for Health and Care Excellence, Guidelines Group, Manchester, UK.
Prof Stavros Petrou, Warwick Medical School, University of Warwick, Coventry, UK.
Dr Leeza Osipenko, PhD, National Institute for Health and Care Excellence, Scientific Advice, London.
Dr Jo Gibbs, PhD, Research Department of Infection & Population Health, University College London, London, UK.
Prof Claudia S Estcourt, FRCP, Barts and the London School of Medicine & Dentistry, Queen Mary University of London, London, UK.
Dr S Tariq Sadiq FRCP, Institute for Infection and Immunity, St George’s, University of London, London, UK.
Prof Ala Szczepura, D Phil, Faculty of Health & Life Sciences, Coventry University, UK.

Background:
Technological advances offer opportunities to redesign existing chlamydia screening/testing and treatment pathways. The potential exists to improve screening uptake (current range 11%-49%) and the proportion of positives successfully treated (range 56%-100%). Innovations underway include self-tests networked through mobile phones, which could be combined with online clinical care and other non-face-to-face care pathways. Evidence of young people’s preferences should be key to informing optimal service re-design.

Aim: To quantify factors influencing young people’s preferences for emerging Chlamydia testing and treatment pathway options.
Methods:

Discrete choice experiment (DCE). Methods used to select attributes and levels included (i) a systematic literature review of stated preference studies for STI testing and treatment published prior to 31 December 2015. Included studies were published in English, included one or more aspect of mainstream STI testing and treatment for any STI, undertaken in an OECD high income country. Key search terms included stated preference, stated choice, DCE, contingent valuation, and conjoint analysis. (ii) four focus groups using staged recruitment to include spread in age range (16-24 years) and other demographic characteristics; (iii) four expert groups including clinicians and researchers. The draft questionnaire tested in a pilot (n=9). The final questionnaire (including 25 pairwise choices with opt-out) was completed online by a national panel of 16-24 year olds across England (YouthSight). Analysis used multinomial logit models and included validity checks.

Findings:

1,230 respondents (response rate 73%). The strongest attribute influencing preferences was Chlamydia test accuracy (OR 3.24, 95% CI 3.13 – 3.36), followed by time to result (OR 1.81, 95% CI 1.71-1.91). Respondents showed a preference for remote Chlamydia testing options (self-testing, self-sampling and postal testing) over attendance at a testing location. A general preference for online (OR 1.21, 95% CI 1.15-1.28) versus traditional GP (OR 1.18 (95% CI 1.12-1.24)/pharmacy (OR 1.15, 95% CI 1.10-1.22)/clinic services (OR 1) was observed for accessing treatment. Little difference observed between face-to-face (OR 1), telephone (OR 0.95, 95% CI 0.90-1), instant messaging (OR 1.03, 95% CI 0.98-1.07) or email (OR 1.05, 95% CI 1-1.10) methods of access. No significant difference in preferences for antibiotic provision e.g. collection from pharmacy (OR 1.07, 95% CI 1.02-1.13) versus postal delivery (home OR 1.01, 95% CI 0.96-1.06, collection point OR 1.03, 95% CI 0.98-1.08).

Interpretation:

This DCE is the first to systematically identify attributes of chlamydia testing and treatment important to young people using primary research and then survey a national pre-defined sample to quantify preferences. DCE coefficients can help estimate uptake probabilities for re-designed chlamydia pathways. Although this DCE was conducted using an online population, which may limit generalizability to other populations, findings could assist technology developers, policy makers, commissioners and service providers to optimise the adoption of emerging technologies and service re-design.

Word Count: 448

Funding Source

This Doctoral Fellowship is supported by the Medical Research Council under the UKCRC Translational Infection Research (TIR) Initiative, (Grant Number G0901608).
Corresponding Author: Mrs Sue Eaton, PhD Student, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK

Contribution of Authors
Sue Eaton – PhD Student, conceived and undertook the research
Dr Deborah Biggerstaff – PhD Supervisor
Dr Joshua Pink - Specialist advice on DCE Design & Analysis
Prof Stavros Petrou – PhD Supervisor
Dr Leeza Osipenko – PhD Supervisor
Dr Jo Gibbs – Clinical input into development of DCE materials (eSTI2 Consortium)
Prof Claudia S Estcourt - Clinical input into development of DCE materials (eSTI2 Consortium)
Dr S Tariq Sadiq - eSTI2 Consortium Principal Investigator
Prof Ala Szczepura – PhD Supervisor (eSTI2 Consortium HTA Lead)

Competing Interests
Sue Eaton – None
Dr Deborah Biggerstaff – None
Dr Joshua Pink - None
Prof Stavros Petrou – None
Dr Leeza Osipenko – None
Dr Jo Gibbs – None
Prof Claudia S Estcourt - None
Dr S Tariq Sadiq - None
Prof Ala Szczepura – None